Investigation of therapeutic efficacy of docetaxel, cisplatin and S1 (DCS) chemotherapy for advanced or recurrent gastric cancer

Investigation of therapeutic efficacy of docetaxel, cisplatin and S1 (DCS) chemotherapy for advanced or recurrent gastric cancer - DCS for advanced gastric cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019972

Enrollment

Registered

2015-12-01

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced/Recurrent Gastric cancer

Interventions

2 courses treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Gastrointestinal cancer

Exclusion criteria

Exclusion criteria: Inadequate renal and liver function

Design outcomes

Primary

Measure	Time frame
Clinical response after 1 month after completion of DCS chemotherapy	—

Secondary

Measure	Time frame
Adverse effect and pathological response	—

Countries

Japan

Contacts

Public ContactKiyohiko Shuto

Teikyo University Chiba Medican Center Surgery

kshuto@med.teikyo-u.ac.jp0436-62-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026